Latest News and Press Releases
Want to stay updated on the latest news?
- 
                            
New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing...
 - 
                            
Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires...
 - 
                            
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
 - 
                            
Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics that sought to block the launch of Liquidia’s YUTREPIA™.
 - 
                            
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of EHang Holdings Limited (NASDAQ: EH) between January 20,...
 - 
                            
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of EHang Holdings Limited (NASDAQ: EH) between January 20,...
 - 
                            
NEW YORK, Dec. 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of EHang Holdings Limited (NASDAQ: EH) between January 20,...
 - 
                            
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of EHang Holdings Limited (NASDAQ: EH) between January 20,...
 - 
                            
BARCELONA, Spain, Feb. 28, 2022 (GLOBE NEWSWIRE) -- In the run up to Rare Disease Day, which is held on 28 February, International pharmaceutical company Ferrer has strengthened its focus on...